Dan Bradbury is a life sciences executive with more than 30 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market, and maximize shareholder value. Prior to serving as Chairman of the Board and CEO at Equillium, Inc., Bradbury held executive roles at BioBrit, LLC, a Life Sciences Consulting and Investment Firm; and San Diego-based Amylin Pharmaceuticals, launching three first-in-class medicines during his tenure.
Bradbury serves on the board of directors for Biocon Limited (BIOCON); BioMed Realty (BMR); Corcept Therapeutics (CORT); Geron Corporation (GERN); Illumina, Inc. (ILMN); Castle Biosciences, Inc.; DiaVacs; Liquid Grids, Inc.; Microdermis, Inc.; Profil Institute for Clinical Research; and Troia Therapeutics, Inc.
He also serves on the Riecken Community Libraries Board, the Investor Growth Capital Advisory Board, the BioMed Ventures Advisory Committee, the University of California San Diego’s Rady School of Management’s Advisory Council, and the RAND Health Board of Advisors.
Bradbury earned a Bachelor of Pharmacy degree from Nottingham University, and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.